December 8, 2020
CONSENSUS STATEMENT BY THE
ANGIOMA ALLIANCE SCIENTIFIC ADVISORY BOARD
ABOUT COVID-19 VACCINE
With anticipated approval by the U.S. Food and Drug Administration, long-awaited COVID-19 vaccines will soon be available. Based on exceptional effectiveness data (greater than 90% protection from COVID-19 illness), the durability of benefit after a recommended second dose, and minimal reported side effects in multiple phases of testing of each vaccine, we strongly recommend that the CCM patient community seek vaccination through any one of the approved vaccines, including any recommended follow-up dose. There is no reason to believe that CCM patients will react any differently to these vaccines than the general population, and no scientific basis to fear the vaccine more than COVID-19, which has taken or interfered with so many lives.
Alliance to Cure Cavernous Malformation Scientific Advisory Board
Dr. Issam Awad, Chair, Alliance to Cure Cavernous Malformation Scientific Advisory Board
University of Chicago Neurosurgery
Dr. Kelly Flemming
Mayo Clinic Rochester Neurology
Dr. Helen Kim
UCSF Anesthesia
Dr. Rustam Al-Shahi Salman
University of Edinburgh Neurology, UK
Dr. Kevin Whitehead
University of Utah Cardiology
Dr. Atif Zafar
St. Michael’s Hospital Neurology, Toronto
Dr. Brent Derry
Hospital for Sick Children Developmental & Stem Cell Biology Program, Toronto
Dr. Angeliki Louvi
Yale University Department of Neurosurgery and Neurosciences
